Abstract
Background Early intervention for individuals with clinical high-risk for psychosis (CHR-P) aims to prevent the onset of serious mental illnesses like schizophrenia, but models for specialized care remain underdeveloped. We describe the development, feasibility, and value of a CHR-P evaluation and treatment program built on learning health system principles. We demonstrate that referral and intake clinical assessment data can improve the characterization and identification of individuals with CHR-P.
Methods The Resilience Evaluation-Social Emotional Training (RE-SET) Program, developed as part of a continuum of psychosis care programs at Massachusetts General Hospital, systematically collects clinical data at referral, intake evaluation, and during treatment. In this study, at referral, providers, caregivers, and/or patients reported on the patient’s psychiatric history. Patients for whom there were concerns for attenuated psychosis were eligible for evaluation. Prior to diagnostic evaluation, patients completed self-report measures of a broad range of psychiatric symptoms. Patients were evaluated with the Structured Interview for Psychosis-Risk Syndromes (SIPS) to determine if they met CHR-P criteria. Using referral and intake data from 118 help-seeking individuals, we performed univariate chi-square or independent samples t-test to identify factors associated with CHR-P syndrome.
Results Ninety-nine (99) individuals with complete referral data were included in the analysis (mean age: 17.8 years; SD: 4). Almost a quarter (24.2%) met CHR-P criteria on the SIPS. Referred individuals presented with high rates of psychiatric comorbidity, previous psychiatric treatment, and functional impairment across multiple domains. Significant predictors (p<.05) of CHR-P syndrome included: history of autism spectrum disorder, endorsing more than one psychotic symptom, reduced sleep duration, and more severe cognitive and behavioral difficulties.
Conclusions Identification of CHR-P may be improved with greater attention to developmental history, psychotic symptoms, sleep disturbance, and cognitive and behavioral difficulties. Integrating routine assessment into clinical care provides data-driven opportunities to improve the identification and treatment of CHR-P.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Foo was supported by funding from the Massachusetts Department of Mental Health to the Massachusetts General Hospital Center of Excellence for Psychosocial and Systemic Research, and the Sidney R. Baer, Jr Foundation. Dr. Donovan was supported by the Massachusetts Department of Mental Health. Dr. Cather was supported by funding from the Massachusetts Department of Mental Health to the Massachusetts General Hospital Center of Excellence for Psychosocial and Systemic Research. Dr. Holt was supported by funding from the National Institute of Mental Health (R01MG127265; R01MH125426; and R01MH122371-SCH), the Massachusetts Department of Mental Health, and the Sidney R. Baer, Jr Foundation. Dr. Clauss was supported by the Dupont Warren Fellowship of Harvard Psychiatry, Louis V. Gerstner Scholar Award, the Chen Institute Mass General Neuroscience Transformative Scholar Award, and the Maryland Psychiatric Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Mass General Brigham Institutional Review Board approved this study, and deemed the study exempt from the requirement to obtain informed consent, since the data were collected for clinical and quality improvement purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Ethical Approval: The Mass General Brigham Institutional Review Board approved this study, and deemed the study exempt from the requirement to obtain informed consent, since the data were collected for clinical and quality improvement purposes.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
- Abbreviations
- CHR-P
- clinical high-risk for psychosis
- RE-SET
- Resilience Evaluation-Social Emotional Training
- SIPS
- Structured Interview for Psychosis-Risk Syndromes
- ASD
- autism spectrum disorder
